612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III

Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study

CRLF2 expression and MRD kinetics outcomes across the age spectrum in Mexican patients with acute lymphoblastic leukemia Prevalence and association with post induction measurable residual disease

From 1968 to 2050 Trends and forecasts of acute lymphoblastic leukemia mortality among older adults in United States

An analysis of the cerebral spinal fluid metabolome during intensive chemotherapy and its association with depressive symptoms in children with acute lymphoblastic leukemia

Early identification of thrombosis risk in adult acute lymphoblastic leukemia

A prospective non randomized controlled study of vaseline medicated gauze for topical management of chemotherapy induced oral mucositis in pediatric hematology patients

Improved survival with intermediate intensity pediatric inspired regimen and allo HSCT in adults with ALL in a resource limited setting

Associations between serum asparaginase activity and asparaginase associated toxicities in pediatric ALL patients receiving calaspargase A report from the DFCI ALL consortium

Balancing risk and benefit Fluoroquinolone prophylaxis in hyper CVAD for acute lymphoblastic leukemia in a high fluoroquinolone resistance setting

CRLF2 rearrangement and extramedullary disease in B cell acute lymphoblastic leukemia A possible link

Real world treatment patterns outcomes and unmet needs in patients with ph ALL receiving tyrosine kinase inhibitors in the United States Emerging trends and the role of asciminib based combinations